Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants
Chang Yi Wang, Kao‐Pin Hwang, Hui-Kai Kuo, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 10
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

A survey of COVID-19 vaccine acceptance across 23 countries in 2022
Jeffrey V. Lazarus, Katarzyna Wyka, Trenton M. White, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 366-375
Open Access | Times Cited: 275
A multinational Delphi consensus to end the COVID-19 public health threat
Jeffrey V. Lazarus, Diana Romero, Christopher J. Kopka, et al.
Nature (2022) Vol. 611, Iss. 7935, pp. 332-345
Open Access | Times Cited: 172
The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far
Vivek P. Chavda, Rajashri Bezbaruah, Kangkan Deka, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1926-1926
Open Access | Times Cited: 72
SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic
Chiranjib Chakraborty, Manojit Bhattacharya, Kuldeep Dhama
Vaccines (2023) Vol. 11, Iss. 3, pp. 682-682
Open Access | Times Cited: 59
How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020–2022
Chih‐Cheng Lai, Ping‐Ing Lee, Po‐Ren Hsueh
Journal of Microbiology Immunology and Infection (2023) Vol. 56, Iss. 3, pp. 433-441
Open Access | Times Cited: 44
Protein subunit vaccines: Promising frontiers against COVID-19
Vivek P. Chavda, Eswara Naga Hanuma Kumar Ghali, Pankti C. Balar, et al.
Journal of Controlled Release (2024) Vol. 366, pp. 761-782
Closed Access | Times Cited: 15
Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses
Chang Yi Wang, Wen‐Jiun Peng, Be-Sheng Kuo, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 4, pp. e1010870-e1010870
Open Access | Times Cited: 24
The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review
Aparajita Sarkar, Sara Omar, Aya Alshareef, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 24
Immunogenic proteins and potential delivery platforms for mpox virus vaccine development: A rapid review
Yang Wang, Kaiwen Yang, Hao Zhou
International Journal of Biological Macromolecules (2023) Vol. 245, pp. 125515-125515
Open Access | Times Cited: 24
COVID-19 Vaccines: Where Did We Stand at the End of 2023?
Kenneth Lundström
Viruses (2024) Vol. 16, Iss. 2, pp. 203-203
Open Access | Times Cited: 9
A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2
Shixia Wang, Chang Yi Wang, Hui-Kai Kuo, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 2724-2734
Open Access | Times Cited: 31
Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China
Hongqin Xu, Hongyan Li, Hailong You, et al.
Emerging Microbes & Infections (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 30
The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development
Haiyun Yu, Fei Guan, Heather Miller, et al.
Emerging Microbes & Infections (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 29
Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies
Pia Gattinger, Anna Ohradanova‐Repic, Rudolf Valenta
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5352-5352
Open Access | Times Cited: 19
The SARS‐CoV‐2 Omicron Variant and its Multiple Sub‐lineages: Transmissibility, Vaccine Development, Antiviral Drugs, Monoclonal Antibodies, and Strategies for Infection Control – a Review
Ranjan K. Mohapatra, Sarika Verma, Venkataramana Kandi, et al.
ChemistrySelect (2023) Vol. 8, Iss. 9
Open Access | Times Cited: 16
Molecular characterization of SARS-CoV-2 nucleocapsid protein
Yanping Huang, Junkai Chen, Siwei Chen, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 6
COVID-19 vaccines: A comprehensive review of safety and efficacy
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 685-777
Closed Access
Transformative Approaches in SARS-CoV-2 Management: Vaccines, Therapeutics and Future Direction
Ankita Saha, Shweta Choudhary, Priyanshu Walia, et al.
Virology (2025) Vol. 604, pp. 110394-110394
Closed Access
Immunobiology and immunotherapy of COVID-19
Kenneth Lundström
Progress in molecular biology and translational science (2025)
Closed Access
Large‐Scale Screening of CD4+ T‐Cell Epitopes From SARS‐CoV‐2 Proteins and the Universal Detection of SARS‐CoV‐2 Specific T Cells for Northeast Asian Population
Yu Zhao, Chengtao He, Min Peng, et al.
Journal of Medical Virology (2025) Vol. 97, Iss. 2
Closed Access
Next-Generation Coronavirus Disease 2019 Vaccines
Kathryn E. Stephenson
Infectious Disease Clinics of North America (2025)
Closed Access
The Spike Protein of SARS-CoV-2 Is Adapting Because of Selective Pressures
Georgina I. López-Cortés, Miryam Palacios-Pérez, Hannya F. Veledíaz, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 864-864
Open Access | Times Cited: 24
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster
Farshad Guirakhoo, Shixia Wang, Chang Yi Wang, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 8, pp. 1401-1406
Open Access | Times Cited: 23
A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452
Eline A. Feitsma, Yester F. Janssen, Hendrikus H. Boersma, et al.
Vaccine (2023) Vol. 41, Iss. 13, pp. 2184-2197
Open Access | Times Cited: 13
Omicron variants breakthrough infection elicited higher specific memory immunity than third dose booster in healthy vaccinees
Pei Yu, Zijian Liu, Zhuoqi Zhu, et al.
Virologica Sinica (2023) Vol. 38, Iss. 2, pp. 233-243
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top